Legal Action Looms as Rocket Pharmaceuticals Faces Class Action Suit Over Recent Allegations

Investor Alert: Legal Action Against Rocket Pharmaceuticals

Pomerantz LLP, a renowned law firm specializing in corporate and securities law, has announced the initiation of a class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). This announcement serves to alert investors who have suffered financial losses related to their investments in Rocket Pharmaceuticals, advising them to consider their options as deadlines approach.

Case Background

The class action targets allegations of securities fraud and other illegal business practices allegedly perpetrated by Rocket Pharmaceuticals and certain named officers and directors. Investors are encouraged to reach out to Pomerantz to discuss potential participation in the lawsuit. They can contact Danielle Peyton via email at [email protected] or by phone at 646-581-9980, extension 7980, or toll-free at 888.4-POMLAW.

Interested parties must act quickly, as the deadline to move the court to appoint a Lead Plaintiff is only days away, specifically by August 11, 2025, for those who purchased Rocket securities during the class period. Further details regarding the complaint can be reviewed at Pomerantz Law Firm's website.

The Trigger Incident

A significant factor contributing to the lawsuit was a press release issued on May 27, 2025. The release disclosed troubling news regarding the company’s RP-A501, an investigational gene therapy for Danon disease. The Press release mentioned that a patient involved in a pivotal Phase 2 trial experienced an unexpected serious adverse event, specifically noting complications associated with capillary leak syndrome, which led to the FDA placing a clinical hold on the trial. Tragically, it was also revealed that the patient subsequently passed away due to an acute systemic infection.

This devastating news had a significant impact on Rocket's stock price, causing a dramatic drop of $3.94 per share, equating to a startling 62.84% decrease, closing at just $2.33 per share on the day of the announcement.

Pomerantz LLP: A Leader in Securities Litigation

Founded by Abraham L. Pomerantz, known as a pioneering figure in class action law, Pomerantz LLP has built a reputation as one of the premier law firms in handling corporate and securities class actions. With offices in major cities, including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, the firm has successfully recovered substantial damages for investors adversely affected by corporate fraud and misconduct over its 85-year history.

While Pomerantz has a track record of achieving notable settlements, potential participants in this lawsuit are reminded that prior results do not guarantee future outcomes. The firm’s proactive approach continues to protect the rights of class members worldwide.

What Investors Should Do

For those impacted by Rocket Pharmaceuticals’ recent developments, taking swift action is crucial. Getting involved in this class action may allow affected investors to reclaim some of their losses. As the deadline approaches, it’s imperative for investors to contact Pomerantz LLP to explore their options while ensuring their position is safeguarded. Investors are advised to include their mailing address, phone number, and number of shares purchased when contacting the firm, which will facilitate better assistance regarding their claims.

In the complex field of securities litigation, having adept legal guidance can significantly impact the outcomes for involved parties, making assistance from established law firms like Pomerantz essential. With ongoing developments on the horizon for Rocket Pharmaceuticals, interested investors should follow the situation closely and maintain communication with their legal team regarding any updates or changes.